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Abstract
Background: Since targeting oxidative stress markers has been recently recognized as a novel therapeutic target in
cancer, it is interesting to investigate whether genetic susceptibility may modify oxidative stress response in cancer.
The aim of this study was to elucidate whether genetic polymorphism in the antioxidant enzymes is associated
with lipid peroxidation in breast cancer.
Methods: We conducted a study among Polish women, including 136 breast cancer cases and 183 healthy
controls. The analysis included genetic polymorphisms in five redox related genes: GPX1 (rs1050450), GPX4
(rs713041), SOD2 (rs4880), SEPP1 (rs3877899) and SEP15 (rs5859), lipid peroxidation, the activities of antioxidant
enzymes determined in blood compartments as well as plasma concentration of selenium – an antioxidant trace
element involved in cancer. Genotyping was performed using the Real Time PCR. Lipid peroxidation was expressed
as plasma concentration of thiobarbituric acid reactive substances (TBARS) and measured with the
spectrofluorometric method. Glutathione peroxidase activity was spectrophotometrically determined in erythrocytes
(GPx1) and plasma (GPx3) by the use of Paglia and Valentine method. Spectrophotometric methods were
employed to measure activity of cytosolic superoxide dismutase (SOD1) in erythrocytes (Beauchamp and Fridovich
method) and ceruloplasmin (Cp) in plasma (Sunderman and Nomoto method). Plasma selenium concentration was
determined using graphite furnace atomic absorption spectrophotometry.
Results: Breast cancer risk was significantly associated with GPX1 rs1050450 (Pro198Leu) polymorphism, showing a
protective effect of variant (Leu) allele. As compared to the control subjects, lipid peroxidation and GPx1 activity
were significantly higher in the breast cancer cases, whereas ceruloplasmin activity was decreased. After genotype
stratification, both GPx1 activity and TBARS concentration were the highest in GPX1 Pro/Pro homozygotes affected
by breast cancer. At the same time, there was a significant correlation between the level of lipid peroxidation and
GPx1 activity among the cancer subjects possessing GPX1 Pro/Pro genotype (r = 0.3043; p = 0.0089), whereas such a
correlation was completely absent in the cases carrying at least one GPX1 Leu allele as well as in the controls
(regardless of GPX1 genotype).
Conclusions: GPX1 polymorphism may be an important factor modifying oxidative stress response in breast cancer
subjects. Further studies are needed to elucidate its potential clinical significance.
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Background
Breast cancer is a multifactorial and a complex disease,
with a major etiological contribution of hormonal origin
and about 5–10 % of risk attributable to the inherited
genetic factors (mainly associated with BRCA1 and
BRCA2 mutations) [1]. Genetic variations associated
with sporadic breast cancer as well as their interactions
with environmental factors are still poorly understood.
Similarly, pathological processes linked to breast cancer
tissue are not entirely explored, though they are gener-
ally associated with oxidative stress [2]. Prooxidant pro-
cesses in breast tissue are mainly linked to lipid
peroxidation, as mammary gland is profusely surrounded
by adipose tissue [2]. Notably, targeting oxidative stress
markers has been recently recognized as a novel thera-
peutic approach in cancer treatment, due to the fact that
generation of reactive oxygen species (ROS) as well as
some products of lipid peroxidation may improve effect-
iveness of the treatment by decreasing cancer progres-
sion and reducing drug resistance. Mechanisms
underlying these effects (and reviewed recently by Bar-
rera [3]) are mainly associated with the induction of
apoptosis in cancer cells by overcoming their antioxidant
defense. The upregulated antioxidant defense is an ex-
tremely important adaptive mechanism in cancer cells,
as it allows them to survive under conditions of perman-
ent oxidative stress, and it is often associated with can-
cer progression and drug resistance. Thus targeting ROS
has been suggested as a potential determinant of effect-
ive treatment in cancer [4, 5].
Since breast cancer is largely associated with lipid per-
oxidation, it may be hypothesized that the disease pro-
gression or response to treatment may highly rely on
patient’s individual ability to scavenge either lipid peroxi-
dation products or reactive species that lead to lipid oxi-
dation (like hydroxyl radical). The interesting issue to be
explored under this approach is whether genetic suscep-
tibility associated with antioxidant system, may modify
the prooxidative effects in breast cancer subjects. It is
well known, that some genetic variations present in the
antioxidant enzymes modify their activity or function,
which may result in the altered ability to scavenge ROS
[6]. These alterations explain some associations between
specific gene variants and breast cancer risk [7–11], sug-
gesting protective role of variants linked to the increased
antioxidant protection. However, when the tumor is
already developed, upregulated antioxidant system may
act in an opposite way, promoting cancer cells growth
and metastasis [12]. One may hypothesize that genetic-
ally determined high ability to scavenge reactive species
and especially lipid peroxidation products, may serve as
a negative prognostic factor in breast cancer subjects.
Natural antioxidant defense consists of many enzym-
atic and nonenzymatic systems that act in concert with
dietary antioxidants [12]. Most important antioxidant
enzymes include superoxide dismutases (SOD), glutathi-
one peroxidases (GPx) and catalase (Cat). SOD (includ-
ing 3 forms: cytosolic - SOD1, mitochondrial - SOD2
and extracellular - SOD3) catalyze dismutation of super-
oxide anion into hydrogen peroxide, whereas Cat and
GPxs reduce hydrogen peroxide, thus preventing pro-
duction of highly toxic hydroxyl radical [13]. Import-
antly, GPxs may also reduce hydroperoxides of
polyunsaturated fatty acids, counteracting toxic effects
of lipid peroxidation. Nonenzymatic endogenous antioxi-
dants (apart from thiols) include metal-binding proteins
which sequester prooxidant metals such as iron and cop-
per [12]. One of the important metal-binding proteins is
ceruloplasmin (Cp). This enzymatic protein binds cop-
per ions (reducing their deleterious effects) and protects
membrane lipids from iron-dependent lipid peroxidation
due to its ferroxidase-type activity [13].
Endogenous antioxidant system is supported by ex-
ogenous factors derived from diet (like vitamins and
trace elements) and the element which probably gained
most of scientific interest in terms of its antioxidant
properties, is selenium (Se). Many experimental and epi-
demiological findings suggest significant role of Se in
cancer, notably both in its prevention and promotion,
though neither one nor the other mechanism is yet fully
understood [14, 15]. It is proposed that Se acts both via
low molecular Se compounds and via specific proteins,
called selenoproteins. Most of these proteins possess
redox activity like for example already mentioned gluta-
thione peroxidases, including GPx1 (cytosolic glutathi-
one peroxidase), GPx2 (gastrointestinal glutathione
peroxidase), GPx3 (plasma glutathione peroxidase),
GPx4 (phospholipid hydroperoxide glutathione peroxid-
ase) and GPx6 (olfactory glutathione peroxidase) [14].
The activity of GPxs largely depend on Se due to its
presence at the active site of these enzymes [16]. There
are also other physiologically important selenoproteins,
like selenoprotein P (SelP), which is responsible for Se
transport or selenoprotein 15 kDa (Sep15), which is in-
volved in protein folding in endoplasmic reticulum [14].
The aim of this study was to investigate the overall
relationship between lipid peroxidation, markers of
antioxidant system and individual genetic susceptibil-
ity linked to antioxidant response in breast cancer
subjects. Lipid peroxidation was measured as plasma
concentration of thiobarbituric acid-reactive sub-
stances (TBARS). Markers of antioxidant system com-
prised the activity of the antioxidant enzymes in
blood compartments (GPx1, GPx3, Cp and SOD1)
and plasma concentration of Se. Polymorphic genes
(Additional file 1: Table S1) covered: GPX1, GPX4,
SEPP1, SEP15 (all encoding selenoproteins) and SOD2
(encoding SOD2).
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Materials and methods
Study group
The study involved 136 cases and 183 women assigned
to the control group. All the subjects were enrolled for
the study in the years 2007–2012. The cases were fe-
male patients of the Copernicus Memorial Hospital in
Lodz, Poland, diagnosed with a primary breast cancer.
Basic epidemiological characteristics (age, BMI, smok-
ing status and menopausal status) were collected using
individual questionnaires, whereas clinical data (histo-
logical type of tumor, tumor stage and grade, receptor
status, treatment) were obtained from medical records.
The controls were selected from the population of the
cross sectional study of nurses and midwives (registered
at the Local Registry of the Chamber of Nurses and
Midwifes in Lodz) who underwent mammography
screening in the course of another study [17]. A de-
tailed description of mammography density assessment
was presented elsewhere [17]. On the basis of mammo-
grams, the women who were reported to have a mass,
distorted architecture, density or calcification in the
breast tissue were excluded from the study (from the
control group). The second selection criterion was
based on the type of work with respect to shifts. Specif-
ically, the women who were reported to work in shifts
(at the time of recruitment) were not included in the
study, because this factor was shown to affect the anti-
oxidant status in the group [18]. A signed informed
consent was obtained from all the participants and the
study was conducted in compliance with the Declar-
ation of Helsinki and with approval by the Local Ethics
Committee (Ethical Institutional Review Board at the
Nofer Institute of Occupational Medicine, Lodz,
Poland, Resolution No 5/2007). Characteristics of the
study groups is presented in Table 1.
Methods
Blood samples (7.5 mL) were collected into heparinized
test tubes free from trace elements and separated by
centrifugation into buffy coat (for DNA isolation),
plasma and erythrocytes. Each fraction was stored at –
20 °C until analysis. Before freezing, erythrocytes were
washed three times in isotonic saline and hemolysates
were prepared followed freezing and thawing two times.
DNA isolation
DNA was isolated from buffy coat, using the QIAamp
DNA Blood Mini Kit (Qiagen, Hilden, Germany) accord-
ing to the manufacturer’s instructions. DNA purity and
quantity were determined with a spectrophotometer
(Eppendorf, Hamburg, Germany) at a wave length of 260
and 280 nm.
SNP genotyping
Allelic discrimination was performed using the Real Time
PCR method and the CFX96™ Real Time PCR Detection
System (Bio-Rad, Hercules, CA, USA). For genes: GPX4
(rs713041), SEPP1 (rs3877899) and SOD2 (rs4880), we
identified SNPs using Taqman® SNP Genotyping Assays
(C_2561693_20, C_8709053_10 and C_2841533_10) and
Taqman Genotyping Master Mix (Life Technologies,
Carlsbad, CA, USA). PCR reactions were carried out with
10 ng of DNA in a final volume of 10 μL, under following
conditions: 10 min at 95 °C enzyme activation and 50
two-step cycles of denaturation at 95 °C for 15 s and an-
nealing at 60 °C for 1 min. For genes: GPX1 (rs1050450)
and SEP15 (rs5859), we employed the High Resolution
Melt Curve technique. Oligonucleotide sequences for PCR
primers, designed by Beacon Designer™ (PREMIER Biosoft,
Palo Alto, CA, USA), were as follows: 5′-GCCGCTTCCA
GACCATTG-3′ (forward) and 5′-GGTGTTCCTCCCTC
GTAG-3′ (reverse) for GPX1, 5′-TTGCGTTAATGAAGA
CTACACAG-3′ (forward) and 5′-AAACATGAAAGAAC
AAACCAGAAG-3′ (reverse) for SEP15. The Real-time
PCR was performed in 20 μL volume, in the presence of
20 ng of genomic DNA, primers (0.5 μM each each), Sso-
Fast™ EvaGreen® Supermix (Bio-Rad, Hercules, CA, USA)
and nuclease-free water. The reaction protocol for both
genes included enzyme activation at 98 °C for 3 min,
followed by 40 two-step cycles of denaturation at 98 °C for
5 s and annealing at 57 °C (for GPX1) or 60 °C (for SEP15)
for 10 s. The protocol for melting curve analysis, performed
immediately after the PCR, included initial DNA denatur-
ation at 95 °C for 1 min, followed by 150 two-step cycles:
DNA renaturation at 65 °C for 1 min and DNA denatur-
ation with the 0.2 temperature increment in each cycle
(from 65 °C to 95 °C in the last cycle). Data analysis was
performed using the Bio-Rad CFX Manager and the Bio-
Rad Precision Melt Analysis Software. Particular genotypes
for GPX1 and SEP15 were identified on the basis of PCR-
RFLP method, using following restriction enzymes: DDeI
(Promega, Madison, WI, USA) fo GPX1 and FspBI (Fer-
mentas, Waltham, MA, USA) for SEP15. Oligonucleotide
sequences for PCR primers were: GPX1 forward 5′-AC
CCTCTCTTCGCCTTCC-3′, GPX1 reverse 5′AGGACCA
GCACCCATCTC-3′, SEP15 forward 5′– GCCTGCTCCT
CAGAGTCTC –3′ and SEP15 reverse 5′–AAACATGA
AAGAACAAACCAGAAG–3′. Digestion products were
158 bp, 232bo, 390 bp for GPX1 and 360 bp, 198 bp,
162 bp for SEP15. Accuracy of Real Time PCR genotyping
was checked by retyping and randomly selected samples
(15 % form cases and controls). The compatibility of the re-
sults was 100 %.
BRCA1 mutation analysis
To exclude hereditary cancer cases attributed to muta-
tions in high penetrance genes, we conducted genotyping
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for the two BRCA1 mutations, which are most frequently
observed among Polish population i.e.,: 5382insC and
T300G (C61G) [19]. Both mutations were identified by
the mismatch PCR and Restriction Fragment Analysis, re-
spectively, using primer sequences as described in Add-
itional file 1: Table S2. For both mutations, the PCR
reactions were performed in a 20 μL volume, containing
100 ng template DNA, primers (1 μM each), 0.5 unit Taq
polymerase (Qiagen, Hilden, Germany), dNTPs (150 μM
each; Qiagen, Hilden, Germany), PCR reaction buffer
(Qiagen, Hilden, Germany) and nuclease-free water. Reac-
tion conditions covered initial DNA denaturation at 94 °C
for 3 min, followed by 40 cycles: DNA denaturation at
94 °C for 45 s, annealing at 62 °C for 45 s and elongation
at 72 °C for 1 min. The final extension was performed at
72 °C for 9 min. The PCR products were digested with en-
donucleases: DDeI (Promega, Madison, WI, USA) for
5382insC and TaaI (Fermentas, Burlington, Canada) for
T300G mutation, according to the conditions described
by suppliers. Digestion products were analyzed using elec-
trophoretic technique in 2 % (w/v) agarose gel. Fragments’
length and interpretation of the results is indicated in
Additional file 1: Table S2.
Lipid peroxidation
Plasma TBARS concentration was determined by the
use of a spectrofluorometric method [20]. TBA-reactive
compounds were extracted to butanol. The value of
fluorescence of butanol layer was read at an excitation
wavelength of λ = 525 nm and emission wavelength of
λ = 547 nm, using the Perkin Elmer Luminescence Spec-
trometer LS50B (Norwalk, Ct, USA). Intraassay variation
(CV) was 3.6 % (n = 8).
Glutathione peroxidase activity
Activity of GPx1 and GPx3 was determined in erythro-
cytes (GPx1) and plasma (GPx3) using the method of
Paglia and Valentine [21] with t-butyl hydroperoxide as
a substrate and following the rate of NADPH oxidation
by the coupled reaction with glutathione reductase. The
Table 1 Characteristics of the study group
Cases Controls p
N 136 183
Age (years) 51.9 ± 6.5 (35–61) 51.4 ± 4.9 (40–60) 0.092a
BMI (kg/m2) 26.7 ± 4.8 (17.1–43.1) 27.2 ± 4.8 (18.6–48.3) 0.611a
Smoking status, n (%)
Ever smokers 82 (60) 110 (60) 0.973b
Never smokers 54 (40) 73 (40)
Current smoking, n (%)
Yes 30 (22) 50 (27) 0.233b
No 106 (88) 133 (73)
Menopausal status (self-reported), n (%)
Postmenopausal 73 (54) 107 (58) 0.944b
Premenopausal 51 (37) 76 (42)
Unknown 12 (9) -
Histological type, n (%)





Tumor stage, n (%)







Tumor grade, n (%)





ER status, n (%)
ER-positive 82 (60) na -
ER-negative 32 (24)
Unknown 22 (16)
PR status, n (%)
PR-positive 78 (57.4) na -
PR-negative 44 (32.3)
Unknown 14 (10.3)
HER2 status, n (%)
HER2-positive 19 (14.0) na -




Yesc 21 (15) na -
No 115 (85)
Data for age and BMI expressed as mean ± standard deviation (range)
IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, DCIS ductal
carcinoma in situ, LCIS lobular carcinoma in situ, ER estrogen receptors, PR
progesterone receptors, HER2 human epidermal growth factor receptors, T
tumor stage, G tumor grade, na not applicable
athe Mann–Whitney test
bthe Chi-squared test
cpatients who underwent chemotherapy or breast cancer surgery
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rate of decrease in the absorbance at 340 nm (being pro-
portional to the GPx activity) was read using the Unicam
UV4 UV/Vis spectrophotometer (Cambridge, UK).
Intraassay variation (CV) was 2.7 % (n = 8) for GPx1 and
2.3 % (n = 7) for GPx3. The samples were analyzed in
single measurements. The measurement was repeated
whenever the value was out of the range.
Superoxide dismutase activity
Activity of SOD1 was determined in erythrocytes by the
use of the method of Beauchamp and Fridovich [22],
which relies on the inhibition by SOD of the reduction
of Nitro Blue Tetrazolium (NBT) by xanthine and
xanthine oxidase. Concentration of the reduced form of
NBT was measured spectrophotometrically at a wave-
length of λ = 540 nm, using the Unicam UV4 UV/Vis
spectrophotometer (Cambridge, UK). Intraassay vari-
ation (CV) was 4.7 % (n = 8).
Ceruloplasmin activity
The oxidase activity of Cp was determined spectro-
photometrically according to the method described by
Sunderman and Nomoto [23], with a PPD (p-phenyl-
enediamine) as a substrate. Absorbance of the oxidation
product was read in Unicam UV4 UV/Vis spectropho-
tometer (Camridge, UK), at a wavelength of λ = 535 nm.
The activity of Cp was expressed as the amount of prod-
uct formed per minute per 1 L of plasma. Intraassay vari-
ation (CV) was 4.7 % (n = 5).
Selenium status
Plasma Se concentration was determined using the
graphite furnace atomic absorption spectrophotometry
with Zeeman background correction, in the Pye Uni-
cam Solaar 989 QZ spectrophotometer (Cambridge,
UK). Lyophilized human serum containing selenium
at a concentration of 78 ng/L (Seronorm™, Nycomed
Pharma AS, Norway) was used as a reference material
for quality control and assurance. Additionally, the
method was checked by participation in the interla-
boratory comparison trials. Limit of detection for Se
was 11 ng/mL and the precision calculated from 10
successive series of microelement determinations in
the reference samples was 6.5 %.
Statistical analysis
Normality for the data was evaluated with the Shapiro-
Wilks test. The analysis of variance (ANOVA) or the
Kruskal-Wallis test were used for the univariate ana-
lysis. Polymorphisms were entered individually into the
ANCOVA model adjusting for clinical variables that
could potentially affect the patient’s TBARS concentra-
tions, including gene-disease interaction. Logistic re-
gression analysis was used to evaluate the association of
particular polymorphisms and their interactions with
the disease status. Analysis of gene-gene interactions
comprised GPX1 x SOD2 and GPX1 x SEPP1 as sug-
gested by literature data [10, 24]. Other higher order in-
teractions between genotypes were not fitted either in
linear or logistic regressions due to the limited sample
size. All the analyses were performed using STATIS-
TICA 10 software package (Statsoft, Tulsa, OK, USA).
All significance tests were two-sided and the statistical
significance was established as p value less than 0.05.
Results
Epidemiological and clinical characteristics of the study
subjects are presented in Table 1. The patients with can-
cer did not differ significantly from the control group in
terms of age, BMI, smoking status or menopausal status
(Table 1). 80 % (109 women) of the cases were subjects
diagnosed with invasive ductal carcinomas and 85 %
(115 women) were before any clinical treatment. All the
cases were negative for 5382insC and T300G (C61G)
BRCA1 mutations.
Distribution of GPX1 (rs1050450), GPX4 (rs713041),
SEPP1 (rs3877899), SEP15 (rs5859) and SOD2 (rs4880)
genotypes in the study participants is presented in
Table 2. Distribution of all alleles of the analyzed SNPs
were in agreement with those expected under the
Hardy-Weinberg equilibrium. Significant differences in
allele frequencies were noted for the GPX1 rs1050450
polymorphism, for which carrying at least one variant al-
lele (GPX1 Leu) was associated with a decreased risk of
cancer both, in the univariate analysis and after adjust-
ment for age, BMI, smoking status and menopausal sta-
tus (Table 2). None of the 4 remaining polymorphisms
showed any associations with the risk of breast cancer.
The analysis of relevant gene-gene interactions was con-
ducted for GPX1 x SOD2 and GPX1 x SEPP1 and did
not reveal any significance (data not shown).
Oxidative stress parameters in the cases and controls
are presented in Table 3. Significantly higher TBARS
levels and GPx1 activity (and p = 0.0003 and p = 0.0036,
respectively) were observed in the women suffering from
breast cancer as compared to the controls, whereas there
were no differences in GPx3 and SOD activity. Also
plasma Se concentration did not differ between the cases
and controls, and accounted for 55.2 μg/L and 57.0 μg/L,
respectively. Ceruloplasmin activity was significantly lower
in the cases as compared to the controls (p = 0.0005;
Table 3). Treatment status did not affect the levels and
activities of the studied parameters, allowing us to retain
the whole group of patients with cancer in further ana-
lyses (Additional file 1: Table S3).
Table 4 presents data on lipid peroxidation in the
study group analyzed with respect to different genotypes.
Carrying the polymorphic variant of the GPX1 gene was
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shown to significantly affect plasma TBARS concentra-
tions, with wild-type homozygotes, having higher levels
than the individuals with at least one polymorphic allele
(p = 0.0320; Table 4). There were no differences in
TBARS levels with respect to other genotypes. Further
investigation of the observed association between GPX1
polymorphism and TBARS was conducted with respect
to disease status, in a multivariate regression model
with age, BMI and smoking status (Table 5). Results
showed that the effect of both malignancy and GPX1
genotypes on TBARS levels is additive rather than con-
ditional (Fig. 1). The patients with cancer showed
TBARS concentrations higher by 0.18 μmol/L, than those
observed in the controls. At the same time, carrying at
least one polymorphic allele at GPX1 was associated
with TBARS levels lower by 0.10 μmol/L. This resulted
in Pro/Pro homozygotes with cancer having the highest
TBARS levels among all the 4 groups (2.74 95 % CI
2.53–2.95). Following that, we investigated whether this
association would be linked directly through GPx1 ac-
tivity. TBARS levels showed a positive correlation with
GPx1 activity, which was close to statistical significance
(r = 0.1056; p = 0.0596). Neither Cp (r = 0.0016; p =
0.9778), SOD1 (r = −0.0262; p = 0.6411), GPx3 (r = 0.0805;
Table 2 Breast cancer risk associated with polymorphic variants in GPX1, GPX4, SEPP1, SEP15 and SOD2 genes
Polymorphism Cases, n (%) Controls, n (%) OR crude (95%CI) p OR adjusteda (95 % CI) p
GPX1 (rs1050450)
Pro/Pro 73 (53.7) 75 (41.0) 1 (ref.) 1 (ref.)
Leu/Leu 12 (8.8) 23 (12.6) 0.54 (0.25–1.16) 0.112 0.61 (0.28–1.34) 0.215
Pro/Leu + Leu/Leu 63 (46.3) 108 (59.0) 0.60 (0.38–0.94) 0.026 0.61 (0.38–0.97) 0.035
GPX4 (rs713041)
CC 44 (32.4) 65 (35.5) 1 (ref.) 1 (ref.)
TT 26 (19.1) 28 (15.3) 1.37 (0.71–2.66) 0.345 1.31 (0.65–2.66) 0.445
CT + TT 92 (67.6) 118 (64.5) 1.15 (0.72–1.85) 0.556 1.12 (0.68–1.85) 0.644
SEPP1 (rs3877899)b
Ala/Ala 81 (60.4) 122 (66.7) 1 (ref.) 1 (ref.)
Thr/Thr 9 (6.7) 6 (3.3) 2.26 (0.77–6.63) 0.136 2.57 (0.86–7.61) 0.087
Ala/Thr + Thr/Thr 53 (39.6) 61 (33.3) 1.31 (0.82–2.08) 0.255 1.38 (0.85–2.23) 0.192
SEP15 (rs5859)
GG 82 (60.3) 103 (56.3) 1 (ref.) 1 (ref.)
AA 8 (5.9) 14 (7.7) 0.72 (0.28–1.80) 0.479 0.72 (0.27–1.91) 0.512
GA + AA 54 (39.7) 80 (43.7) 0.85 (0.54–1.33) 0.473 0.91 (0.57–1.46) 0.696
SOD2 (rs4880)
Ala/Ala 29 (21.3) 50 (27.3) 1 (ref.) 1 (ref.)
Val/Val 32 (23.5) 41 (22.4) 1.34 (0.70–2,59) 0.371 1.54 (0.76–3.14) 0.227
Ala/Val + Val/Val 107 (78.7) 133 (72.7) 1.39 (0.82–2.35) 0.221 1.67 (0.95–2.96) 0.076
Significant p values are presented in bold
OR odds ratio, 95 % CI 95 % confidence interval
aOR adjusted for age, BMI, menopausal status and smoking (ever, never)
bgenotype status was unknown in the case of 2 individuals
Table 3 Oxidative stress parameters in the breast cancer cases and controls
Parameter Cases (n = 136) Controls (n = 183) pa (vs controls)
GPx1 activity [U/g Hb] 22.3 ± 5.5 (11.1–35.0) 20.5 ± 4.7 (10.7–29.7) 0.0036
GPx3 activity [U/mL] 0.189 ± 0.037 (0.108–0.308) 0.191 ± 0.032 (0.125–0.297) 0.7491
SOD1 activity [U/mg Hb] 6.84 ± 1.24 (4.48–11.53) 6.90 ± 1.52 (3.03–10.91) 0.8590
Cp activity [g/L] 0.58 ± 0.18 (0.13–1.05) 0.66 ± 0.21 (0.31–1.75) 0.0005
TBARS concentration [μmol/L] 2.62 ± 0.96 (1.01–5.27) 2.24 ± 0.83 (1.00–5.90) 0.0003
Se concentration [μg/L] 55.2 ± 14.7 (23.2–99.9) 57.0 ± 11.8 (29.1–97.7) 0.1791
Data expressed as mean ± standard deviation and (range). Significant p values are presented in bold
athe Mann–Whitney test
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p = 0.1514) activities nor Se concentration (r = 0.0141; p =
0.801) showed such associations. However, we did not
observe any direct associations between GPx1 activity and
the GPX1 rs1050450 polymorphic allele presence in the
univariate analysis (p = 0.2669) or after adjustment for age,
BMI, smoking status and Se status (beta = − 0.07; p =
0.2618, Table 5). Interaction between the presence of ma-
lignancy (the disease status) and GPX1 genotype was not
significant (p = 0.2897), although Pro/Pro homozygotes
with cancer showed GPx1 activity higher by 1.5–2.0 U/g
Hb than all the other variants (Table 5, Fig. 2). Given the
significant impact of the disease and genotype at
rs1050450 on TBARS and the apparent correlation be-
tween GPx1 activity and TBARS, we evaluated whether
the latter effect is in fact group-dependent (Fig. 3). Among
the individuals with the Pro/Pro genotype, the correlation
between TBARS concentration and GPx1 activity was
positive and significant (r = 0.3043; p = 0.0089) but it was
absent in the cancer patients who had one or two poly-
morphic GPX1 Leu alleles (r = 0.0417; p = 0.7454). This
effect was completely absent in the Pro/Pro controls who
obviously had the lowest range of both TBARS and GPx1
Table 4 Plasma TBARS concentration in all the individuals (cases and controls), data stratified according to the genotype
Polymorphism Genotype N TBARS concentration [μmol/L] pa (ANOVA) pb (vs wild type homozygote)
GPX1 (rs1050450) Pro/Pro 148 2.32 (1.80–3.09) 0.0527
Pro/Leu 136 2.15 (1.69–2.64)
Leu/Leu 35 2.29 (1.75–2.94)
Pro/Leu + Leu/Leu 171 2.18 (1.70–2.73) 0.0320
GPX4 (rs713041) CC 109 2.23 (1.82–2.85) 0.4266
CT 156 2.21 (1.75–2.89)
TT 54 2.38 (1.86–3.07)
CT + TT 210 2.34 (1.76–2.94) 0.3237
SEPP1 (rs3877899)c Ala/Ala 203 2.26 (1.76–2.94) 0.9393
Ala/Thr 99 2.21 (1.74–2.87)
Thr/Thr 15 2.05 (1.65–2.93)
Ala/Thr + Thr/Thr 114 2.19 (1.74–2.87) 0.7802
SEP15 (rs5859) GG 185 2.26 (1.78–2.93) 0.8028
GA 112 2.22 (1.69–2.92)
AA 22 2.03 (1.75–2.86)
GA + AA 134 2.21 (1.73–2.89) 0.5357
SOD2 (rs4880) Ala/Ala 79 2.32 (178–3.00) 0.8902
Ala/Val 167 2.23 (1.76–2.87)
Val/Val 73 2.22 (1.69–2.92)
Ala/Val + Val/Val 240 2.23 (1.74–2.88) 0.6891
Data expressed as median values and (25 and 75 % percentiles). Significant p values are presented in bold
athe Kruskal-Wallis test
bthe Mann–Whitney test
cgenotype status was unknown in the case of 2 individuals
Table 5 Multivariate regression model for the factors associated with TBARS concentration and GPx1 activity
TBARS - Beta (ß) TBARS – p GPx1 – Beta (ß) GPx1– p
Age 0.1281 0.0277 0.1378 0.0230
BMI 0.0986 0.0926 −0.0192 0.7523
Smoking status −0.0227 0.6817 −0.1126 0.0491
Selenium a a −0.0877 0.1212
GPX1 Pro/Pro vs Pro/Leu + Leu/Leu −0.1150 0.0403 −0.0652 0.2618
Disease status 0.1940 0.0005 0.1383 0.0163
GPX1 Pro/Pro vs Pro/Leu + Leu/Leu a Disease status 0.0269 0.6278 0.0610 0.2897
Significant values are presented in bold
afactor not included in the model
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(r = −0.0015; p = 0.9897) as well as in the controls positive
for the Leu allele (r = −0.034; p = 0.7262).
Discussion
The role of lipid peroxidation in breast cancer remains
not fully elucidated. The main focus of this study was to
investigate whether lipid peroxidation in breast cancer
subjects is associated with genetic polymorphism of anti-
oxidant enzymes. In addition, we analyzed the risk of
breast cancer in association with selected gene variants
as well as with Se status.
Lipid peroxidation in breast cancer – link with GPX1
polymorphism and GPx1 activity
We observed a higher concentration of TBARS in
plasma of the breast cancer cases as compared to the
healthy women. This observation is consistent with the
general observation of increased lipid peroxidation in
breast cancer. Numerous studies have shown increased
levels of different markers of lipid peroxidation (TBARS
or specific aldehydes like malondialdehyde, 8-F2 isopros-
tanes or 4-hydroksynonenal) in plasma, serum, urine
and also, in some cases, in cancer tissue of the women suf-
fering from breast cancer [24–30]. In our study, increased
plasma lipid peroxidation in cancer subjects was accom-
panied by the increased activity of GPx1 (Table 3), sup-
porting other findings on the altered antioxidant
homeostasis in breast cancer [24–30]. Interestingly, we
observed a positive correlation between plasma TBARS
concentration and GPx1 activity measured in blood eryth-
rocytes of the breast cancer subjects. So far, few authors
have investigated the correlation between lipid peroxida-
tion and activity of antioxidant enzymes in cancer pa-
tients, focusing rather on the differences between the
selected parameters. Interestingly, the correlation between
plasma lipid peroxidation and erythrocyte glutathione per-
oxidase seems to depend on health status, being for
example positive in healthy subjects and negative in the
subjects undergoing chronic hemodialysis [31, 32]. Tas et
al. have investigated such a relationship in breast cancer
patients, showing no correlation between MDA levels and
GPx1 activity in cancer tissue though both parameters
were significantly increased as compared to benign tumors
[30]. However, the positive correlation has been found in
the same study between MDA levels and the activity of
Cat (the enzyme which similarly as GPx1, catalyzes the
reduction of hydrogen peroxide).
Additionally, in our study we observed that TBARS
concentration was associated with GPX1 rs1050450
polymorphism (Tables 4 and 5). This SNP is linked to
the amino acid substitution, from proline (Pro) to leu-
cine (Leu), and this change was shown to affect GPx1
activity, with the polymorphic variant (Leu) being less
responsive to Se as observed in vitro, in human breast
cancer cells (MCF-7) [33]. In our previous observa-
tional study we have found that the correlation between
GPx1 activity and plasma Se concentration in humans
seems to depend on GPX1 polymorphism, being signifi-
cant only among individuals carrying at least one Pro
allele [34]. In this study we failed to indicate a signifi-
cant effect of GPX1 polymorphism on GPx1 activity in
the whole group. However, the SNP effect seemed to be
preserved among cancer cases, with Pro/Pro cancer
homozygotes having the highest GPx1 activity as com-
pared to other groups. Furthermore, only in this genotype
group there was a significant and positive correlation
between GPx1 activity and lipid peroxidation. This obser-
vation suggests that GPX1 rs1050450 polymorphism may
actually determine not only the response of GPx1 activity
to Se supplementation, but also its response to lipid per-
oxidation (and generally oxidative stress), at least in breast
cancer subjects.
Fig. 1 Additive effect of GPX1 rs1050450 variants and the disease
status on the plasma TBARS concentration. Data adjusted for age,
BMI, current smoking and selenium
Fig. 2 GPx1 activity depending on GPX1 rs1050450 polymorphism
and the disease status. Data adjusted for age, current smoking
and selenium
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Since lipid peroxidation products have been recently
recognized as a therapeutic target in cancer, the possible
relationship between lipid peroxidation and GPX1 poly-
morphism could have a potential role in breast cancer
treatment. Notably it has been already observed that
products of lipid peroxidation may modulate processes
crucial in the breast cancer survival [2]. Thus it may be
speculated that GPX1 polymorphism may affect breast
cancer treatment via modulating lipid peroxidation. It
remains to be elucidated, which genotype would be
more favorable in terms of a better therapy outcome.
One could expect the individuals with GPX1 Pro/Pro to
be less vulnerable to prooxidant effects of the treatment
due to a higher antioxidant response under a permanent
stress condition. The rationale for this assumption is
supported by studies which indicated that increased
GPx1 activity was associated with anticancer drug resist-
ance [35, 36]. Possible role of GPX1 polymorphism in
modifying the response to anticancer therapy has already
been suggested by Zhao et al. These authors conducted
a prospective study on 224 patients with bladder cancer
and observed that individuals possessing Pro/Pro geno-
type had shorter recurrence–free survival as compared
to those with at least one variant (Leu) allele [37]. A
significant protective effect of Leu alleles was observed
only among the whites (n = 202) with a hazard ratio
(HR) of 0.63; 95 % CI 0.42–0.96. Interestingly, after data
stratification according to sex, the effect was preserved
only among women. The authors of this study suggest
that the unexpectedly observed protective effect of Leu
allele may be explained by the fact that the patients with
a reduced activity of ROS scavenging enzymes may have
better prognosis after cancer treatment as most of the
therapies (immunotherapy, chemotherapy, radiotherapy)
are based on ROS generation [37].
Breast cancer risk associated with SNPs in the antioxidant
enzymes
Breast cancer risk was significantly associated with GPX1
rs1050450 polymorphism in this study. In this study we
observed that carrying Leu variant was associated with a
significant 40 % decrease in the risk (Table 2). These find-
ings are not consistent with the results of the recent study
by Meplan et al., in which GPX1 Leu/Leu genotype has
been linked to a significantly increased risk of breast
cancer (adjusted OR = 1.88; 95%CI 1.08–3.28) [38]. The
results of earlier case control studies on breast cancer risk
and GPX1 rs1050450 polymorphism are also inconsistent
between each other, showing lack of any associations or
the increased risk linked to the carriage of the variant
allele [8, 39–41]. Recent meta-analysis performed by Hu
et al., which covered 5509 breast cancer cases and 6542
controls from 6 case control studies, has not revealed any
association among the whites and has suggested that the
polymorphic variant may increase the risk only among
Africans [42]. However, the meta-analysis has not consid-
ered histopathological type of breast cancer and it is likely
that since there are different risk factors for ductal and
Fig. 3 Correlation between TBARS and GPx1 activity depending on the disease status and the GPX1 genotype. Correlation coefficients in the breast
cancer cases
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non-ductal breast cancer, the effects of SNPs may also
vary considerably [43]. Notably, the significant association
for GPX1 polymorphism in the mentioned study by
Meplan et al., has been restricted only to the non-ductal
cancers [38]. Nevertheless, we did not expect to find
significant odds ratios in this study (it was not the main
aim of the study) due to the small sample size, and there
is a high probability that the observed effect of GPX1 poly-
morphism could occur by chance. However, it has been
the first such a study regarding sporadic breast cancer risk
and GPX1 polymorphism conducted among Polish
women, and considering the fact that similar protective
effect of GPX1 Leu variant has been found in Polish
population also in the case of lung and laryngeal can-
cers [44], the presented results deserve further investi-
gation. For other investigated SNPs: rs713041 (GPX4),
rs3877899 (SEPP1), rs5859 (SEP15) and rs4880 (SOD2),
we failed to find any associations with the breast cancer
risk. Similarly, we did not observe any significant gene-
gene interactions of potential interest as suggested by
other studies, including GPX1 x SOD2 and GPX1 x
SEPP1 [8, 38].
Breast cancer risk and Se status
In the study presented here, plasma Se concentration
was relatively low (29.1–99.9 μg/L; Table 3) in all the
study participants (being consistent with the fact of
low dietary Se intake in Polish population [45]). How-
ever, it was not associated with the breast cancer risk.
In general, the association between breast cancer and
Se status remains controversial. Some case control
studies have indicated the increased risk linked to the
low dietary intake of the element, its low concentra-
tion in plasma/serum or low content in toe nails [46,
47] but no such association has been found in other
studies, both with a retrospective [48] and a prospect-
ive approach [49–52]. Interestingly, the authors of
one case control study, in which serum Se has been
found to be lower in the breast cancer women (n = 200) as
compared to the healthy controls (n = 200), have con-
cluded that altered Se status was a consequence rather
than a cause of cancer [46]. Potentially protective activity
of Se compounds against breast cancer has been suggested
on the basis of in vitro and in vivo observations, indicating
for the regulatory activity of Se on estrogen receptors
expression [53–55]. In the light of epidemiological data
however, including our study, link between Se and breast
cancer remains still elusive.
Limitations of the study
Results of this study could have been biased by non-
random selection of the control subjects. It should be
noted that the study presented here was not a typical
case control study. Thus, we were not able to assign the
same confounders to both groups (cancer cases and con-
trol subjects) and cannot rule out that the observed as-
sociations were not influenced by potential confounding
factors, not controlled for in the study (as for example
diet or supplements use). Nevertheless, both groups
were residents of the same area, and were not different
in terms of age, BMI, smoking status and menopausal
status. It should be also appreciated that all the subjects
enrolled in the control group had negative screening
mammograms and this information was crucial in the
assessment of biochemical processes linked to breast
cancer. Another weakness of the study concerns rela-
tively small sample size, which limited the possibility to
include more potentially important modifiers of both
GPx1 activity and TBARS levels, such as for example ER
status. Finally, this study lacked data on patients’ sur-
vival, which obviously would give further insights into
the clinical significance of the observed association
between lipid peroxidation and GPX1 polymorphism.
Conclusions
Up to date, no studies have been conducted on the as-
sociation between individual genetic background and
markers of prooxidative effects in breast cancer. The
results of this study suggest that GPX1 polymorphism
may be an important factor that modifies oxidative
stress response in breast cancer. The potential link may
have great significance in terms of potential implication
in tumor progression or treatment thus these findings,
if replicated elsewhere, require further investigation.
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